Shots: ASPECT-NP study (N=726) assessing ZERBAXA 3g IV (ceftolozane & tazobactam) vs. Meropenem 1g IV every eight hrs. for 8 to 14 days/ 14 days for Pseudomonas aeruginosa infection ASPECT-NP resulted in affinity of ZERBAXA for treating HABP and VABP in patients, which will further help in filling sNDA to the US and EMA seeking […]Read More
